SEC Filing Summary: Big Rock Partners Acquisition Corp. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Big Rock Partners Acquisition Corp. (not NRX Pharmaceuticals, Inc., which is the target of a proposed business combination) on January 20, 2021, reporting events occurring on January 15, 2021. The registrant is a Special Purpose Acquisition Company (SPAC) listed on the NASDAQ Stock Market.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance and listing status.
Material Changes and Events
- Nasdaq Listing Extension: The Nasdaq Hearings Panel granted the Company's request to extend its listing deadline to May 24, 2021.
- Compliance Issues: The extension addresses two prior non-compliance notices:
- Failure to complete a business combination within 36 months of its IPO (Rule IM-5101-2).
- Failure to hold an annual stockholder meeting for the fiscal year ended December 31, 2019, by December 31, 2020 (Rule 5820).
- Proposed Business Combination: The Company is pursuing a merger with NeuroRx, Inc. (NeuroRx).
Guidance, Outlook, and Risks
Conditions for Continued Listing: The Panel's decision is conditional upon the Company completing the Business Combination with NeuroRx on or before May 24, 2021, and demonstrating compliance with all initial listing requirements for the combined entity.
Risks and Contingencies:
- Delisting Risk: If the Business Combination is not completed by the Extended Date or if listing requirements are not met, securities will be suspended from trading on Nasdaq.
- Termination Risk: The Business Combination is subject to closing conditions and may be terminated if not consummated by April 23, 2021.
- Forward-Looking Statements: Management expects to complete the transaction but explicitly states it cannot assure success.
Investor Verification Checklist
- Verify the status of the proposed Business Combination with NeuroRx, Inc. and whether the April 23, 2021, termination deadline has been met or extended.
- Monitor the upcoming Form S-4 registration statement for details on the proxy statement and prospectus.
- Confirm whether the combined entity will meet Nasdaq initial listing requirements upon closing.
- Review the December 17, 2020, Form 8-K for detailed closing conditions and termination rights.